Abstract
The factors influencing the final height of central precocious puberty patients treated with gonadotrophin releasing hormone (GnRH) analogues remain a critical issue. This study compares the predicted final height before and after GnRH analogue therapy to identify predictive factors for final height. Fourteen girls with idiopathic central precocious puberty were treated with a GnRH analogue. All had an active non-regressive form before therapy, full and permanent suppression of oestrogenic activity during therapy (duration >2 years, 3.1±0.3 years, mean ±SEM), and the pubertal pituitary-ovarian axis had normalized in all of them 1 year after the cessation of therapy. The mean predicted final height increased from 152±1.8 cm before therapy to 162.2±1.2 cm (P<0.01) at the last evaluation performed 4.5±0.3 years after the onset of therapy. The mean gain in predicted final height between the onset of therapy and the last evaluation was 10.2±1.1 cm. It was correlated with the following data recorded at the onset of therapy: bone age advance over chronological age (r=0.66,P<0.02), predicted final height at the onset of therapy (r=−0.76,P<0.001), and the difference between the target height and the predicted height at onset of therapy (r=0.76,P<0.001). We conclude that GnRH analogue therapy is more likely to improve final height prognosis in girls who initially present with a markedly advanced bone age and a great difference between their target and predicted heights. Both these parameters reflect the severity of the disease at diagnosis.
Similar content being viewed by others
Abbreviations
- FSH:
-
follicle stimulating hormone
- GnRH:
-
gonadotrophin releasing hormone
- LH:
-
luteinizing hormone
References
Bayley N, Pinneau SR (1952) Tables for predicting adult height from skeletal age: revised for use with Greulich Pyle hand standards. J Pediatr 50:432–441
Boepple PA, Mansfield MJ, Crawford JD, Crigler JF Jr, Link K, Blizzard RM, Crowley WF Jr (1988) The effects of gonadal sex steroids and their reversible suppression on statural growth and skeletal maturation in girls with central precocious puberty. In: Disorders of human growth. Advances in research and treatment. Grave GD, Cassorea FG (eds) Thomas, Springfield, Ill, pp 312–328
Brauner R, Malandry F, Fontoura M, Prévot C, Souberbielle JC, Rappaport R (1991) Idiopathic central precocious puberty in girls as a model of the effect of plasma estradiol level on growth, skeletal maturation and plasma IGFI. Horm Res 36:116–120
Comite F, Cassorea F, Barnes KM, Hench KD, Dwyer A, Skerda MC, Loriaux DL, Cutler GB Jr, Pescovitz OH (1986) Luteinizing hormone releasing hormone analogue therapy for central precocious puberty: long term effect on somatic growth, bone maturation and predicted height. JAMA 255:2613–2616
Fontoura M, Brauner R, Prevot C, Rappaport R (1989) Precocious puberty in girls: early diagnosis of a slowly progressing variant. Arch Dis Child 64:1170–1176
Greulich WW, Pyle SI (1959) Radiographic atlas of skeletal development of the hand and wrist, 2nd edn. Stanford University Press, Stanford
Kreiter M, Burstein S, Rosenfield RL, Moll GW Jr, Cara JF, Youseffzadeh DK, Cuttler L, Levitsky LL (1990) Preserving adult height potential in girls with idiopathic true precocious puberty. J Pediatr 117:364–370
Manasco PK, Pescovitz OH, Feuillan PP, Hench KD, Barnes KM, Jones J, Hill SC, Loriaux DL, Cutler GB Jr (1988) Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. J Clin Endocrinol Metab 67:368–372
Manasco PK, Pescovitz OH, Hill SC, Jones JM, Barnes KM, Hench KD, Loriaux DL, Cutler GB Jr (1989) Six-year results of luteinizing hormone releasing hormone (LHRH) agonist treatment in children with LHRH-dependent precocious puberty. J Pediatr 115:105–108
Rappaport R, Fontoura M, Brauner R (1987) Treatment of central prococious puberty with an LHRH agonist (Buserelin): effect on growth and bone maturation after three years of treatment. Horm Res 28:149–154
Tanner JM, Goldstein H, Whitehouse RH (1970) Standards for children's height at ages 2–9 years allowing for height of parents. Arch Dis Child 47:755–762
Zachmann M, Sobradillo B, Frank M, Frisch H, Prader A (1978) Bayley-Pinneau, Roche-Wainer-Thissen, and Tanner height predictions in normal children and in patients with various pathologic conditions. J Pediatr 93:749–755
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brauner, R., Malandry, F. & Rappaport, R. Predictive factors for the effect of gonadotrophin releasing hormone analogue therapy on the height of girls with idiopathic central precocious puberty. Eur J Pediatr 151, 728–730 (1992). https://doi.org/10.1007/BF01959077
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01959077